ClinicalTrials.gg
Active, not recruitingNCT05479994Updated Mar 4, 2026

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 2 interventional study of BGB-11417 in Leukemia, Lymphoma and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by BeiGene. Active, not recruiting at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 11 under way, 4 of them phase 3. sonrotoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 11
100 · median 100
Started
2022
the only one that year
Phase 2
5 of 11
3 open now
Primary completion
2025-01
later than 0 of 10 live
Registered
1st of 11
by date
Lead sponsor
1 of 11
BeiGene

Among the 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 1st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sonrotoclax

sonrotoclax: first FDA approval 2026 (BEQALZI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

03

Conditions studied

  • Leukemia
  • Lymphoma
  • Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Small Lymphocytic Lymphoma
  • Relapsed Chronic Lymphocytic Leukemia

Browse trials for

Keywords

  • Refractory Chronic Lymphocytic Leukemia
  • Leukemia
  • Lymphoma
  • Small Lymphocytic Lymphoma
04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 100 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Participants with a confirmed diagnosis of CLL/SLL based on the International Workshop on CLL (iwCLL) criteria:

    1. Treatment intolerance or failure during or after treatment with chemoimmunotherapy (CIT) and BTK inhibitors (BTKi) or
    2. Treatment intolerance or failure during or after treatment with BTKi for CIT-ineligible participants as assessed by the investigator.
  2. Participants who require treatment based on the iwCLL 2018 criteria
  3. (ECOG) Performance Status score of 0 to 2
  4. of > 6 month

Key Exclusion Criteria

  1. Prior within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or low risk (Gleason score ≤ 6) localized prostate cancer
  2. Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results
  3. A known history of or currently suspected Richter's syndrome
  4. Prior stem cell transplant (unless ≥ 3 months after transplant) or prior chimeric cell therapy (unless ≥ 6 months after cell infusion)
  5. Prior allogeneic stem cell transplant

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Participants will receive BGB-11417 orally until disease progression, intolerable toxicity, or other scenarios specified in the protocol

    Drug: BGB-11417

Interventions

  • Administered orally

    Also known as: sonrotoclax

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)

    Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for partiticpants with small lymphocytic lymphoma (SLL)

    Time frame: Up to 2 Years

Secondary outcomes

  1. Overall Response Rate (ORR) as assessed by the investigator

    Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for participants with small lymphocytic lymphoma (SLL)

    Time frame: Up to 2 Years

  2. Duration of response (DoR) as determined by the IRC and the investigator

    DoR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first

    Time frame: Up to 5 Years

  3. Progression Free Survival (PFS) as determined by the IRC and the investigator

    PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 5 Years

  4. Time to Response (TTR) as assessed by investigator and IRC

    TTR is defined as the time from treatment initiation to the first documented response.

    Time frame: Up to 2 Years

  5. Overall Survival (OS)

    defined as time from the start of treatment to the date of death due to any cause

    Time frame: Up to 5 Years

  6. Participants Reported Outcome as measured by EQ-5D-5L questionnaires

    The EQ-5D-5L descriptive system assesses health in five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY / DEPRESSION), each of which has five levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems/unable to).

    Time frame: Up to 5 Years

  7. Participant Reported Outcomes as measured by NFLymSI-18

    The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index-18 (NFLymSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score.

    Time frame: Up to 5 Years

  8. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    with adverse events leading to discontinuation, and AEs graded according NCI-CTCAE Version 5 and the Grading Scale for Hematologic Toxicity in CLL Studies

    Time frame: Up to 5 Years

  9. Number of participants with clinically significant changes from baseline in vital signs

    Vital signs include systolic and diastolic blood pressure, heart rate, and body temperature

    Time frame: Up to 5 Years

  10. Number of participants with clinically significant changes from baseline in clinical laboratory values

    Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis

    Time frame: Up to 5 Years

  11. Number of Participants With Clinically Significant Physical Examination Findings

    A full physical examination includes head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal and musculoskeletal systems

    Time frame: Up to 5 Years

08

Study locations

50 sites
09

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jan 2025, 26 months.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 26 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2022
First posted
Jul 29, 2022
StartActual
Oct 25, 2022
Primary completionActual
Jan 24, 2025
CompletionEst.
Aug 25, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05479994
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Oct 25, 2022
Primary completion
Jan 24, 2025
Completion
Aug 25, 2027 (estimated)
Last update
Mar 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion